[Science Advances] Investigators isolated multiple distinct single-cell clones from the SUM149PT human breast cell line spanning the epithelial-to-mesenchymal transition spectrum having diverse migratory, tumor-initiating, and metastatic qualities, including three unique intermediates.
[Science Translational Medicine] The authors demonstrated that spontaneous triple-negative breast cancer tumors from a genetically engineered mouse model, multiple patient-derived xenografts, and archival patient samples exhibited large populations in vivo of hybrid E/M cells that lead invasion ex vivo while expressing both epithelial and mesenchymal characteristics.
[Annals of Biomedical Engineering] Scientists present an image processing and segmentation pipeline for the detection of 3D GFP-fluorescent triple-negative breast cancer cell nuclei, and they performed quantitative analysis of the formed spatial patterns and their temporal evolution.
[Endocrine-Related Cancer] Investigators compile the current knowledge demonstrating the altered expression of splicing variants and spliceosomal components in BCa, showing the existence of a growing body of evidence supporting the close implication of the alteration in the splicing process in mammary tumorigenesis.
[PLoS One] Scientists examined the effect of glucose as well as its deprivation, and antagonism using the non-metabolized analogue 2-deoxy glucose, on the proliferation of several breast cancer cell lines MCF7, MDA-MB-231, YS1.2 and pII and one normal breast cell line, using the MTT assay.
[TR1X, Inc. (GlobeNewswire)] Tr1X announced that the US FDA has cleared the Company’s Investigational New Drug application for TRX319, an allogeneic, off-the-shelf CAR-Tr1 Treg cell therapy, in progressive multiple sclerosis.
[Nature Aging] Researchers found that splenic T cells exhibit greater functional decline than lymph node T cells within the same aged mouse, prompting investigation into how the aged spleen contributes to T cell aging.
[Nature Nanotechnology] The authors review advances in nanotechnology in the context of parallel progress in cancer antigen discovery, nucleic acid vaccine engineering, and clinical trial designs that may enable therapeutic vaccines to effectively enhance patient survival.